ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer
Maintenance treatment in multiple myeloma: A new era
Preclinical models for small-cell lung cancer
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia
Background of the KEYLYNK-007 trial for advanced solid tumours
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib